



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 37185

Title: Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus

Reviewer’s code: 00722050

Reviewer’s country: Canada

Science editor: Ya-Juan Ma

Date sent for review: 2018-01-31

Date reviewed: 2018-02-05

Review time: 5 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

COMMENTS TO AUTHORS

This prestigious work of Prof. Stremmel working group is pillar and has remarkable importance for the HCV infection platform and the direct-acting antiviral therapy.



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 37185

Title: Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus

Reviewer's code: 03538158

Reviewer's country: Japan

Science editor: Ya-Juan Ma

Date sent for review: 2018-02-09

Date reviewed: 2018-02-11

Review time: 2 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

COMMENTS TO AUTHORS

1. In abstract section: "Between January 2014 and December 2016, 39 patients with HCV reinfection after liver transplantation were treated at our tertiary referral center with sofosbuvir (SOF)-based regimens, including various combinations with interferon (IFN), daclatasvir (DAC), simeprevir (SIM) and/or ledipasvir (LDV). Thirteen patients were treated with SOF + IFN ± RBV. Ten patients were treated with SOF + DAC ± RBV. Eighteen patients were treated with fixed-dose combination of SOF + LDV ± RBV. One patient was treated with SOF + SIM + RBV. Three patients with relapse were retreated with SOF + LDV + RBV." These comments did not match with the text. 2. In Core tip section, what is "recirrrosis"??



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 37185

Title: Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus

Reviewer's code: 01221188

Reviewer's country: Japan

Science editor: Ya-Juan Ma

Date sent for review: 2018-02-09

Date reviewed: 2018-02-12

Review time: 3 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Major revision The patients treated with IFN and without IFN are mixed in this study. Therefore, the meaning of "all patients" is not clear. For instance, in page 9, SVR section, "all patients had attained SVR at 24 wk (SVR24)". However, three patients developed the recurrence with 4 wk after the end of treatment. Does "all patients" mean the patients treated without IFN? It might be better that the patients with treated IFN are excluded from the study. Minor revisions 1) When were the three patients experiencing relapse treated with fixed-dose combination of SOF + LDV? 2) The cause of re-transplantation is not clear. One was due to liver failure. What is the other's cause? 3) The liver histology and the source of infection should be added to table 1. 4) The dose of DAAs and PEG-IFN should be described in the text.



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 37185

Title: Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus

Reviewer's code: 02441161

Reviewer's country: China

Science editor: Ya-Juan Ma

Date sent for review: 2018-02-09

Date reviewed: 2018-02-14

Review time: 5 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This excellent study written by Rupp C et al. has perfectly gone through the knowledge of the safety and efficiency of novel DAAs in liver-transplanted patients with recurrence of HCV infection in a real-world cohort at their tertiary care center. They found DAAs are safe and very efficient in HCV patients after liver transplantation, even in case of cirrhosis or history of relapse after pegylated-interferon therapy. The authors elucidate the therapeutic options that the high SVR rates, despite the many patients with cirrhosis, may argue for a 24-wk therapy period in patients with risk factors for therapy failure in a posttransplant setting. I thoroughly enjoyed reading this manuscript, especially, the outcomes that can be achieved. The manuscript comprehensively reviewed key articles addressed on this issue and well organized them. It should be of large interest for the readers of WJG, and I strongly recommend it to be published in the



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

present form.



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 37185

Title: Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus

Reviewer's code: 00013080

Reviewer's country: Greece

Science editor: Ya-Juan Ma

Date sent for review: 2018-01-31

Date reviewed: 2018-02-15

Review time: 15 Days

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

COMMENTS TO AUTHORS

The article by Rupp et al is a retrospective analysis of the efficacy and safety of DDAs in pts who had undergone liver transplatation and had recurrent HCV infection. The articleiw well written Minor comments 1. why did the authors included only those with at had LT > 6-mo ? 2. how many pts had evidence of HCC before LT. More details regarding size of HCC 3. Why did the authors use SVR 24? do they believe that we need 24 w FU instead of 12w after the end of DDAs treatment?